Entera Bio Accelerates EB613 Phase 3 Trial with Streamlined Protocol

Event summary

  • Entera Bio submitted a streamlined Phase 3 protocol for EB613, aiming for a 12-month primary endpoint instead of 24 months.
  • The company will use a single-tablet formulation (Next-Gen EB613) in the Phase 3 trial, replacing the previous multi-tablet version.
  • Topline data from the Phase 3 trial is anticipated in the second half of 2028, about a year earlier than previously expected.
  • Entera plans to initiate the Phase 3 study in late 2026 and will run a 12-month extension study in parallel with potential NDA review.

The big picture

Entera Bio's submission marks a strategic shift in the osteoporosis treatment landscape, aiming to bring the first oral anabolic therapy to market. The streamlined Phase 3 protocol could accelerate approval timelines, but success hinges on FDA acceptance and competitive differentiation against established injectable therapies like Forteo®. The move reflects broader industry trends toward oral peptide and protein replacement therapies, potentially transforming treatment paradigms for chronic conditions.

What we're watching

Regulatory Alignment
Whether the FDA will accept the streamlined protocol and 12-month primary endpoint for approval.
Execution Risk
The pace at which Entera can enroll 750 patients in the multinational Phase 3 trial.
Commercial Strategy
How Entera positions EB613 against Eli Lilly's Forteo® in the anabolic osteoporosis treatment market.